en
Scientific article
English

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group

Published inAntimicrobial agents and chemotherapy, vol. 44, no. 11, p. 3155-3157
Publication date2000
Abstract

We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

Keywords
  • Anti-HIV Agents/ therapeutic use
  • Delavirdine/ therapeutic use
  • Double-Blind Method
  • Drug Resistance, Microbial
  • Drug Therapy, Combination
  • HIV Infections/ drug therapy
  • HIV Reverse Transcriptase/genetics
  • HIV-1/drug effects/genetics
  • Humans
  • Treatment Outcome
  • Zidovudine/therapeutic use
Citation (ISO format)
JOLY, V. et al. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. In: Antimicrobial agents and chemotherapy, 2000, vol. 44, n° 11, p. 3155–3157.
Main files (1)
Article
accessLevelRestricted
Identifiers
ISSN of the journal0066-4804
453views
0downloads

Technical informations

Creation06/21/2010 10:24:57 AM
First validation06/21/2010 10:24:57 AM
Update time03/14/2023 3:44:18 PM
Status update03/14/2023 3:44:17 PM
Last indexation02/12/2024 6:32:33 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack